InnoCare and KeyMed Together Partner with Prolium Bioscience to Develop ICP-B02
Shots:
- InnoCare & KeyMed together have signed an exclusive license agreement with Prolium to develop & commercialize ICP-B02 (CM355)
- Prolium gains exclusive rights to develop, manufacture & commercialize ICP-B02 globally (non-oncology) and in ex-Asia regions (oncology) while InnoCare & KeyMed will get a total of ~$520M (upfront & near-term payments), minority equity stake in Prolium, clinical, regulatory & commercial milestones plus tiered royalties
- ICP-B02 (CD20×CD3 BsAb), developed by InnoCare & KeyMed, is under P-I/II trial in China for r/r NHL with early results favoring IV & SC forms, especially for FL & DLBCL. A dose expansion study combining ICP-B02 with immunochemotherapies is planned, with IND approval secured
Ref: Businesswire | Image: InnoCare & KeyMed
Related News:- Fermion Technology and Simcere Pharma Join Hands to Develop FZ002-037 for Pain Management
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
